A Phase Ii Evaluation of Nintedanib (Bibf-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An Nrg Oncology/Gynecologic Oncology Group Study
AuthID
P-00V-T6C
P-00V-T6C
© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service